Guardian Capital LP Boosts Stock Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Guardian Capital LP boosted its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMOGet Rating) by 10.4% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 8,924 shares of the medical research company’s stock after acquiring an additional 844 shares during the quarter. Guardian Capital LP’s holdings in Thermo Fisher Scientific were worth $4,848,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of TMO. Mirae Asset Global Investments Co. Ltd. raised its position in Thermo Fisher Scientific by 16.2% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 51,855 shares of the medical research company’s stock valued at $30,628,000 after purchasing an additional 7,238 shares in the last quarter. Kingfisher Capital LLC raised its position in Thermo Fisher Scientific by 1.6% during the 1st quarter. Kingfisher Capital LLC now owns 8,200 shares of the medical research company’s stock valued at $4,843,000 after purchasing an additional 133 shares in the last quarter. Investors Research Corp raised its position in Thermo Fisher Scientific by 1,071.4% during the 2nd quarter. Investors Research Corp now owns 82 shares of the medical research company’s stock valued at $45,000 after purchasing an additional 75 shares in the last quarter. GW&K Investment Management LLC bought a new stake in Thermo Fisher Scientific during the 1st quarter valued at $201,000. Finally, SOL Capital Management CO raised its position in Thermo Fisher Scientific by 2.1% during the 2nd quarter. SOL Capital Management CO now owns 2,068 shares of the medical research company’s stock valued at $1,124,000 after purchasing an additional 43 shares in the last quarter. Hedge funds and other institutional investors own 86.50% of the company’s stock.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 8,200 shares of the business’s stock in a transaction dated Thursday, November 3rd. The stock was sold at an average price of $487.45, for a total transaction of $3,997,090.00. Following the sale, the chief executive officer now owns 178,005 shares in the company, valued at approximately $86,768,537.25. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other news, CEO Marc N. Casper sold 8,100 shares of the company’s stock in a transaction dated Monday, November 7th. The stock was sold at an average price of $493.16, for a total value of $3,994,596.00. Following the sale, the chief executive officer now owns 178,005 shares in the company, valued at $87,784,945.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Marc N. Casper sold 8,200 shares of the company’s stock in a transaction dated Thursday, November 3rd. The stock was sold at an average price of $487.45, for a total value of $3,997,090.00. Following the completion of the sale, the chief executive officer now owns 178,005 shares in the company, valued at approximately $86,768,537.25. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 26,300 shares of company stock worth $13,091,386. 0.43% of the stock is currently owned by insiders.

Thermo Fisher Scientific Stock Performance

Thermo Fisher Scientific stock traded up $2.54 during trading hours on Thursday, hitting $547.29. 823,632 shares of the stock traded hands, compared to its average volume of 1,753,300. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.74 and a quick ratio of 1.22. The firm’s 50 day moving average price is $518.12 and its 200-day moving average price is $541.95. The stock has a market capitalization of $214.65 billion, a price-to-earnings ratio of 30.76, a P/E/G ratio of 1.89 and a beta of 0.83. Thermo Fisher Scientific Inc. has a 1 year low of $475.77 and a 1 year high of $672.34.

Thermo Fisher Scientific announced that its Board of Directors has approved a share repurchase program on Thursday, November 10th that authorizes the company to repurchase $4.00 billion in outstanding shares. This repurchase authorization authorizes the medical research company to buy up to 2% of its stock through open market purchases. Stock repurchase programs are typically a sign that the company’s leadership believes its shares are undervalued.

Thermo Fisher Scientific Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, January 16th. Shareholders of record on Thursday, December 15th will be paid a dividend of $0.30 per share. The ex-dividend date of this dividend is Wednesday, December 14th. This represents a $1.20 annualized dividend and a yield of 0.22%. Thermo Fisher Scientific’s payout ratio is presently 6.75%.

Wall Street Analyst Weigh In

TMO has been the subject of a number of research analyst reports. Credit Suisse Group decreased their target price on Thermo Fisher Scientific to $620.00 in a research report on Thursday, October 27th. Citigroup reduced their price target on Thermo Fisher Scientific from $715.00 to $650.00 and set a “buy” rating for the company in a research report on Thursday, October 27th. Barclays reduced their price target on Thermo Fisher Scientific from $595.00 to $575.00 and set an “overweight” rating for the company in a research report on Thursday, October 27th. SVB Leerink reduced their price target on Thermo Fisher Scientific from $590.00 to $555.00 and set an “outperform” rating for the company in a research report on Thursday, October 27th. Finally, Morgan Stanley reduced their price target on Thermo Fisher Scientific from $678.00 to $613.00 and set an “overweight” rating for the company in a research report on Thursday, October 27th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Thermo Fisher Scientific presently has an average rating of “Moderate Buy” and a consensus price target of $619.00.

Thermo Fisher Scientific Company Profile

(Get Rating)

Thermo Fisher Scientific Inc offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Featured Stories

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.